Zai Lab Ltd 9688.HK :
* ZAI LAB ANNOUNCES STRATEGIC PARTNERSHIP AND GLOBAL LICENSE
AGREEMENT WITH MEDILINK THERAPEUTICS FOR A NEXT GENERATION
ANTIBODY-DRUG CONJUGATE PROGRAM IN ONCOLOGY
* ZAI LAB LTD - UNDER TERMS OF AGREEMENT, MEDILINK WILL BE
ELIGIBLE TO RECEIVE CERTAIN UPFRONT FEES AND DEVELOPMENT
* ZAI LAB LTD - UNDER TERMS, MEDILINK WILL BE ELIGIBLE TO
RECEIVE
SALES-BASED MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON
GLOBAL ANNUAL NET SALES
* ZAI LAB LTD - UNDER TERMS, MEDILINK WILL BE ELIGIBLE TO
RECEIVE
POTENTIAL THIRD-PARTY SUBLICENSING PAYMENTS
* ZAI LAB LTD - ZAI LAB WILL BE RESPONSIBLE FOR ALL
DEVELOPMENT
AND COMMERCIALIZATION ACTIVITIES GLOBALLY
Source text for Eikon: ID:nGNX9NZyng
Further company coverage: 9688.HK